Development of a Claims-Based Algorithm for Use in Patients with Migraine to Identify Potentially Undiagnosed Chronic Migraine Patients (P3.132)

Objective: To develop a claims-based algorithm for use in people with migraine to identify potentially undiagnosed chronic migraine (CM). Background: Approximately 75–80% of persons meeting criteria for CM do not report having received an accurate diagnosis. Design/Methods: An observational study using claims and survey data was conducted in a large medical group. Eligible patients were ≥18 years and had continuous enrollment and a migraine diagnosis in the 12 months prior to screening. Patients with a prior CM diagnosis or migraine-related onabotulinumtoxinA claim were excluded. A physician-administered Semi-Structured Diagnostic Interview (SSDI), the study gold standard for identifying CM, was administered to a convenience sample. The SSDI included 31 questions related to headache symptoms, frequency, disability, medication use, and diagnosis. A multivariate logistic regression model identified potential predictors of CM based on claims data in the 12 months prior to study enrollment. Variables that were significantly different in bivariate analyses (p Results: Of the 108 patients, 64 were SSDI+ and 44 were SSDI−. Four statistically significant predictors of CM status were identified: ≥15 claims (vs Conclusions: The claims-based algorithm for identification of undiagnosed CM patients demonstrated acceptable sensitivity and specificity, and can be used in healthcare settings to improve diagnosis and management of CM patients who may not otherwise be detected. Study Supported by: Allergan plc Disclosure: Dr. Pavlovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc and the American Headache Society. Dr. Yu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc employee. Dr. Yu holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Yu was involved as an investigator. Dr. Yu holds stock and/or stock options in Allergan plc. Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Receives honoraria from Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; eNeura; ElectroCore Medical, LLC; Labrys Biologics; Medscape, LLC; Medtronic, Inc.; Neuralieve; NINDS; Pfizer, Inc.; and Teva Pharmaceuticals. Dr. Silberstein has received research support from His employer receives research support from Allergan, Inc.; Amgen; Cumberland Pharmaceuticals, Inc.; ElectroCore Medical, Inc.; Labrys Biologics; Eli Lilly and Company; Merz Pharmaceuticals; and Troy Healthcare. Dr. Reed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Vedanta Research. Dr. Reed holds stock and/or stock options in Vedanta Research, which sponsored research in which Dr. Reed was involved as an investigator. Dr. Reed has received research support from Managing Director of Vedanta Research, which has received research funding from Allergan, Amgen, Dr. Reddy’s Laboratories, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., and Novartis, via grants to the National Headache Foundation. Vedanta Research ha. Dr. Kawahara has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has served as a consultant Allergan and is a full-time employee of the DaVita Medical Group. Dr. Cowan has nothing to disclose. Dr. Dabbous has nothing to disclose. Dr. Campbell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc employee. Dr. Campbell holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Campbell was involved as an investigator. Dr. Campbell holds stock and/or stock options in Allergan plc. Dr. Shewale has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Shewale holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Shewale was involved as an investigator. Dr. Shewale holds stock and/or stock options in Allergan plc. Dr. Pulicharam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hs served as a consultant and received consulting fees from DaVita Medical Group. Dr. Kowalski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc employee. Dr. Kowalski holds stock and/or stock options in Allergan plc, which sponsored research in which Dr. Kowalski was involved as an investigator. Dr. Kowalski holds stock and/or stock options in Allergan plc. Dr. Viswanathan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Viswanathan holds stock and/or stock options in Yes, Allergan plc, which sponsored research in which Dr. Viswanathan was involved as an investigator. Dr. Viswanathan holds stock and/or stock options in Yes, Allergan plc. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has reviewed for the NIA and NINDS, serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmit. Dr. Lipton has received royalty, license fees, or contractual rights payments from Receives royalties from Wolff’s Headache, 8th Edition, Oxford University Press, 2009 and Informa. Dr. Lipton holds stock and/or stock options in Holds stock options in eNeura Therapeutics and Biohaven. Dr. Lipton has received research support from Support from the NIH, the Migraine Research Foundation, the National Headache Foundation, Allergan plc, Amgen, Dr Reddy’s, and Novartis.